Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Locke FL, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–54.

Article  CAS  PubMed  Google Scholar 

Gardner RA, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood J Am Soc Hematol. 2017;129(25):3322–31.

CAS  Google Scholar 

Raje N, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Warner KD, Hajdin CE, Weeks KM. Principles for targeting RNA with drug-like small molecules. Nat Rev Drug Discov. 2018;17(8):547–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fraietta JA, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dotti G, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mamonkin M, et al. Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol Res. 2018;6(1):47–58.

Article  CAS  PubMed  Google Scholar 

Fry TJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–8.

Article  CAS  PubMed  Google Scholar 

Huang Y et al. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies. Drug Resist Updates, 2024; 101082.

Ye J, et al. Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer. J Translational Med. 2024;22(1):171.

Article  CAS  Google Scholar 

Smith GR, et al. The current landscape of optogenetics for the enhancement of adoptive T-cell therapy. Discovery Immunol. 2025;4(1):kyae019.

Article  CAS  Google Scholar 

Jacobson CA, Maus MV. C (h) AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. Blood Adv. 2020;4(22):5858–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gupta A, Gill S. CAR-T cell persistence in the treatment of leukemia and lymphoma. Leuk Lymphoma. 2021;62(11):2587–99.

Article  CAS  PubMed  Google Scholar 

Gomes-Silva D, et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 2017;21(1):17–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silbert SK, et al. CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy. J Immunother Cancer. 2024;12(10):e009499.

Article  PubMed  PubMed Central  Google Scholar 

Depil S, et al. Off-the-shelf’allogeneic CAR T cells: development and challenges. Nat Rev Drug Discovery. 2020;19(3):185–99.

Article  CAS  PubMed  Google Scholar 

Li Y-R et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol, 2024:1–16.

Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brentjens RJ et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science translational medicine, 2013. 5(177):177ra38-177ra38.

Orlowski RJ, Porter DL, Frey NV. The promise of chimeric antigen receptor T cells (CAR-Ts) in leukaemia. Br J Haematol. 2017;177(1):13–26.

Article  PubMed  Google Scholar 

Wang Y, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41(14):2594–606.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schuster SJ, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134:6.

Article  Google Scholar 

Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28.

Article  CAS  PubMed  Google Scholar 

Munshi NC, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.

Article  CAS  PubMed  Google Scholar 

Berdeja JG, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24.

Article  CAS  PubMed  Google Scholar 

Cohen EE, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67.

Article  CAS  PubMed  Google Scholar 

Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag, 2019: 323–35.

Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood J Am Soc Hematol. 2016;127(26):3321–30.

CAS  Google Scholar 

Davila ML et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014. 6(224):224ra25-224ra25.

Hernandez I, et al. Changes in list prices, net prices, and discounts for branded drugs in the US, 2007–2018. JAMA. 2020;323(9):854–62.

Article  PubMed  PubMed Central  Google Scholar 

Mardiana S, et al. Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression. Sci Transl Med. 2019;11(495):eaaw2293.

Article  CAS  PubMed  Google Scholar 

Mamonkin M, et al. A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood J Am Soc Hematol. 2015;126(8):983–92.

CAS  Google Scholar 

Pan J, et al. S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. Hemasphere. 2023;7(S3):e3515785.

Article  PubMed Central  Google Scholar 

Shi M, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nat Commun. 2024;15(1):3371.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang LY, et al. Clinical characteristics and prognosis of acute myeloid leukemia patien